作者
Lieke HJ Simkens, Harm van Tinteren, Anne May, Albert J ten Tije, Geert-Jan M Creemers, Olaf JL Loosveld, Felix E de Jongh, Frans LG Erdkamp, Zoran Erjavec, Adelheid ME van der Torren, Jolien Tol, Hans JJ Braun, Peter Nieboer, Jacobus JM van der Hoeven, Janny G Haasjes, Rob LH Jansen, Jaap Wals, Annemieke Cats, Veerle A Derleyn, Aafke H Honkoop, Linda Mol, Cornelis JA Punt, Miriam Koopman
发表日期
2015/5/9
期刊
The Lancet
卷号
385
期号
9980
页码范围
1843-1852
出版商
Elsevier
简介
Background
The optimum duration of first-line treatment with chemotherapy in combination with bevacizumab in patients with metastatic colorectal cancer is unknown. The CAIRO3 study was designed to determine the efficacy of maintenance treatment with capecitabine plus bevacizumab versus observation.
Methods
In this open-label, phase 3, randomised controlled trial, we recruited patients in 64 hospitals in the Netherlands. We included patients older than 18 years with previously untreated metastatic colorectal cancer, with stable disease or better after induction treatment with six 3-weekly cycles of capecitabine, oxaliplatin, and bevacizumab (CAPOX-B), WHO performance status of 0 or 1, and adequate bone marrow, liver, and renal function. Patients were randomly assigned (1:1) to either maintenance treatment with capecitabine and bevacizumab (maintenance group) or observation (observation group …
学术搜索中的文章
LHJ Simkens, H van Tinteren, A May, AJ ten Tije… - The Lancet, 2015